Skip to main content
. Author manuscript; available in PMC: 2014 Mar 26.
Published in final edited form as: J Am Coll Cardiol. 2013 Mar 26;61(12):1250–1258. doi: 10.1016/j.jacc.2012.12.034

Figure 3. Sensitivity Analysis.

Figure 3

Cost-effectiveness of statins was most sensitive to the risk of rhabdomyolysis in patients at lower baseline cardiovascular risk; an increase in the rate of rhabdomyolysis in 50 year-old women with moderate hypertension makes statins considerably less cost-effective.